Trial reportDrug design, development and therapy2025
Bioequivalence Study of Palbociclib Tablets in Healthy Volunteers.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Bioequivalence of palbociclib tablets was evaluated in healthy volunteers under fasting and fed conditions in this study. Methods: This bioequivalence trial, which randomized subjects to receive palbociclib under fed or fasted conditions, generated these results. High-performance liquid chromatography-mass spectrometry (HPLC-MS) was employed to determine palbociclib concentrations in plasma from collected blood samples. Pharmacokinetic (PK) parameters were calculated using the non-compartmental analysis (NCA) module within Phoenix WinNonlin version 8.2. Statistical analysis of key pharmacokinetic parameters-maximum plasma concentration (C Results: The geometric mean ratios (T/R) of C Conclusion: The result indicated that the test preparation and the reference preparation of palbociclib tablets were bioequivalent under the fasted and fed conditions. The safety of the two preparations was good. Clinical Trial Registration: This trial was registered on the Chinese Clinical Trial website (http://www.chinadrugtrials.org.cn/index.html # CTR20220977).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.